TCI GENE Inc.

Equities

6879

TW0006879000

Healthcare Facilities & Services

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
80.8 ^TWD	-4.04%		+4.26%	-3.92%

Mar. 15	TCI GENE Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TCI GENE Inc. Announces Cash Dividend, Payable on December 06, 2023	CI

TCI GENE Inc. announced that it expects to receive TWD 577.5 million in funding from Qisda Corporation and other investors

May 19, 2022

TCI GENE Inc. announced a private placement of 5,000,000 shares at an issue price of TWD 115.5 for gross proceeds of TWD 577,500,000 on May 20, 2022. The transaction will include participation from new investor, Qisda Corporation for 4,720,000 shares representing 17.84% stake for gross proceeds of TWD 545,160,000 and other investors. The transaction has been approved by the board of directors of the company and investor.

The payment period for the transaction is from May 23, 2022 to May 25, 2022.

Latest news about TCI GENE Inc.

TCI GENE Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
TCI GENE Inc. Announces Cash Dividend, Payable on December 06, 2023	23-10-19	CI
TCI GENE Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-04	CI
TCI GENE Inc. Announces Resignation of Irene Yen as Company's Financial Officer	23-01-31	CI
TCI GENE Inc. Announces Consolidated Revenue for the Month December 2022 and for January Through December 2022	23-01-06	CI
TCI GENE Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended November 2022	22-12-06	CI
TCI GENE Inc. Announces the Resignation of Lin Yu Chun as Director, Effective December 25, 2022	22-10-20	CI
TCI GENE Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended September 2022	22-10-05	CI
TCI GENE Inc. Announces Change of the Company's Representative of Institutional Director	22-09-30	CI
TCI GENE Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended July 2022	22-08-09	CI
TCI Gene Inc. Reports Revenue for the Month of June 2022	22-07-07	CI
TCI GENE Inc. Announces Board Changes	22-06-30	CI
TCI GENE Inc. Announces Consolidated Revenue Results for the Month and Year to Date Ended May 2022	22-06-06	CI
TCI GENE Inc. announced that it expects to receive TWD 577.5 million in funding from Qisda Corporation and other investors	22-05-19	CI
TCI GENE Inc. Announces Consolidated Revenue Results for the Month and Year to Date Ended April 2022	22-05-06	CI
TCI GENE Inc. Appoints Members of the Risk Management Committee with Effect from May 6, 2022	22-05-06	CI
TCI GENE Inc. Appoints Lin Yung-Hsiang as New Member of the Nomination Committee with Effect from May 6, 2022	22-05-06	CI
TCI GENE Inc. Approves Cash Dividend for the Year Ended December 31, 2021	22-04-22	CI
TCI GENE Inc. Announces Resignation of Chen Ching Ting as Institutional director, Effective June 29, 2022	22-04-13	CI
TCI GENE Inc. Reports Consolidated Revenue Results for the Month and Year to Date Ended March 2022	22-04-05	CI
TCI GENE Inc. Announces First Nominating Committee Establishment	22-03-22	CI
TCI GENE Inc. Appoints Fu Chen Chen as General Manager, Effective March 23, 2022	22-03-22	CI
TCI GENE Inc. Announces First Term of Audit Committee	22-03-17	CI
TCI GENE Inc. Appoints Lin Yung Hsiang as Chairman	22-03-17	CI
TCI GENE Inc. Reports Consolidated Revenue Results for the Month of February 2022	22-03-07	CI

Chart TCI GENE Inc.

Duration

Period

More charts

Company Profile

TCI Gene Inc is a Taiwan-based company mainly engaged in the provision of genetic testing services. The main products include genetic testing services, virus testing services, cell experiment services, production of adipose-derived stem cell preparations for the treatment of degenerative arthritis and knee cartilage defects, production of natural killer cell preparations for the treatment of solid cancer, and personalized genetic health food. Genetic testing technology is mainly in the field of disease risk and drug genetic testing, including comprehensive genetic testing, child growth and development genetic testing, youth beauty genetic testing, weight management genetic testing, anti-aging genetic testing, cardiovascular drug genetic testing and depression/insomnia Pharmacogenetic testing. The Company's products are mainly sold in Taiwan.

Sector

Healthcare Facilities & Services

More about the company

Income Statement Evolution

More financial data

Sector Medical & Diagnostic Laboratories

	1st Jan change	Capi.
TCI GENE INC.	-3.92%	68.33M
SONIC HEALTHCARE LIMITED	-17.89%	8.36B
RADNET, INC.	+39.95%	3.6B
GUANGZHOU KINGMED DIAGNOSTICS GROUP CO., LTD.	-39.11%	2.73B
SYNLAB AG	-8.06%	2.47B
DR. LAL PATHLABS LIMITED	-7.35%	2.32B
NEOGENOMICS, INC.	-11.62%	1.77B
FLEURY S.A.	-18.96%	1.55B
DIAN DIAGNOSTICS GROUP CO.,LTD.	-40.66%	1.22B
METROPOLIS HEALTHCARE LIMITED	+7.56%	1.09B

Medical & Diagnostic Laboratories